Anaptysbio Stock Alpha and Beta Analysis
| ANAB Stock | USD 16.84 0.87 4.91% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as AnaptysBio. It also helps investors analyze the systematic and unsystematic risks associated with investing in AnaptysBio over a specified time horizon. Remember, high AnaptysBio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to AnaptysBio's market risk premium analysis include:
Beta 1.74 | Alpha 0.0422 | Risk 6.65 | Sharpe Ratio 0.0499 | Expected Return 0.33 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
AnaptysBio |
AnaptysBio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. AnaptysBio market risk premium is the additional return an investor will receive from holding AnaptysBio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AnaptysBio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate AnaptysBio's performance over market.| α | 0.04 | β | 1.74 |
AnaptysBio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of AnaptysBio's Buy-and-hold return. Our buy-and-hold chart shows how AnaptysBio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.AnaptysBio Market Price Analysis
Market price analysis indicators help investors to evaluate how AnaptysBio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading AnaptysBio shares will generate the highest return on investment. By understating and applying AnaptysBio stock market price indicators, traders can identify AnaptysBio position entry and exit signals to maximize returns.
AnaptysBio Return and Market Media
The median price of AnaptysBio for the period between Fri, Dec 13, 2024 and Thu, Mar 13, 2025 is 16.34 with a coefficient of variation of 16.28. The daily time series for the period is distributed with a sample standard deviation of 2.7, arithmetic mean of 16.6, and mean deviation of 1.92. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | AnaptysBio stock hits 52-week low at 14.11 amid market challenges - Investing.com | 12/23/2024 |
2 | Acquisition by Ecor1 Capital, Llc of 65184 shares of AnaptysBio at 12.9182 subject to Rule 16b-3 | 12/30/2024 |
3 | Acquisition by Ecor1 Capital, Llc of 13268 shares of AnaptysBio at 12.9268 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Ecor1 Capital, Llc of 6646 shares of AnaptysBio at 12.9506 subject to Rule 16b-3 | 01/02/2025 |
5 | Disposition of 34678 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3 | 01/03/2025 |
6 | Disposition of 17850 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3 | 01/06/2025 |
7 | Acquisition by Eric Loumeau of 7288 shares of AnaptysBio subject to Rule 16b-3 | 01/16/2025 |
8 | Acquisition by Schmid John P. of 16510 shares of AnaptysBio at 14.83 subject to Rule 16b-3 | 01/22/2025 |
9 | Disposition of 6387 shares by Daniel Faga of AnaptysBio at 15.3 subject to Rule 16b-3 | 01/24/2025 |
10 | EcoEngineers Expands Accreditation and Scope Extensions in Canada and Beyond | 01/29/2025 |
11 | Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and ... | 02/11/2025 |
12 | AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment | 02/12/2025 |
13 | AnaptysBio Surges 30.5 percent Is This an Indication of Further Gains | 02/13/2025 |
14 | Acquisition by Daniel Faga of 107350 shares of AnaptysBio subject to Rule 16b-3 | 02/14/2025 |
15 | AnaptysBio, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/27/2025 |
16 | ANABs Certificate Accreditation Program Issues Transition Plan for Latest Version of ANSIASTM E2659 Standard | 02/28/2025 |
17 | Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat | 03/06/2025 |
About AnaptysBio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including AnaptysBio or other stocks. Alpha measures the amount that position in AnaptysBio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 50.35 | 145.75 | 163.01 | 171.16 | PTB Ratio | 3.33 | 6.55 | 5.3 | 7.69 |
AnaptysBio Upcoming Company Events
As portrayed in its financial statements, the presentation of AnaptysBio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of AnaptysBio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of AnaptysBio. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with AnaptysBio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out AnaptysBio Backtesting, AnaptysBio Valuation, AnaptysBio Correlation, AnaptysBio Hype Analysis, AnaptysBio Volatility, AnaptysBio History and analyze AnaptysBio Performance. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
AnaptysBio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.